Revolution Medicines Reports Pancreatic Cancer Drug Data at ASCO
New results for Revolution Medicines' daraxonrasib were presented at the ASCO conference over the weekend. A pancreatic cancer expert described an emotional reaction after treating patients with the data.
StatNew data on Revolution Medicines' pancreatic cancer treatment drew a standing ovation at the ASCO conference held over the weekend immediately prior to June 1, 2026. The results were described as practice-changing in related STAT headlines published May 31, 2026. ” STAT published an article on June 1, 2026, covering the weekend's ASCO presentations.
The piece was written by Biotech Correspondent Meghana Keshavan, who covers biotech and contributes to The Readout newsletter.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
New ScientistPhase 3 Trial Finds Daraxonrasib Extends Median Survival to 13 Months vs 7 Months for Chemotherapy in Second-Line Pancreatic Cancer
A 500-person study found the once-daily pill halted or reversed tumor progression in nearly one-third of patients versus 10 percent on chemotherapy. Median survival rose from less than seven months to roughly 13 months.
nypost.comBundibugyo Ebola Strain Shows High Survival Rate in DRC; Suspected Cases Reported in Brazil and Italy
Four nurses and one laboratory worker have recovered from Ebola caused by the Bundibugyo strain in the Democratic Republic of Congo. Suspected cases linked to travel from affected countries are under investigation in Brazil and Italy.
Wildfire Insured Losses Hit $54 Billion in 2025, Highest on Record
A new analysis published Sunday found that insured losses from wildfires worldwide hit at least $54 billion in 2025, the highest level on record. The Los Angeles fires and blazes in South Korea and Spain drove the total.